Impax Laboratories Receives Tentative Approval for Generic Coreg CR Extended-Release Capsules
Impax Laboratories, Inc. (NASDAQ:IPXL) has received tentative US FDA approval on its Abbreviated New Drug Application. The application was for a generic form of Coreg CR (carvedilol phosphate) extended-release capsules, in quantities of 10, 20, ... [Read]
Impax Laboratories Being Investigated For Merger with Amneal Pharmaceuticals
The Impax Laboratories (NASDAQ:IPXL) Board of Directors is being investigated by the stock legal firm Brower Piven in regards to its impending merger with Amneal Pharmaceuticals. Brower Piven is looking into prospective breaches of fiduciary ... [Read]
Impax Laboratories Inc. Plunges 5.74% During Monday Trading
As of Monday trading on November 13th, Impax Laboratories Inc. (NASDAQ:$IPXL) plunged a cool 5.74%, or a loss of $-1.05 per share, to close at $17.25. Impax Laboratories is a pharmaceutical company, developing and commercializing ... [Read]
Head-to-Head: Impax Laboratories VS. SCYNEXIS
Impax Laboratories (NASDAQ:$IPXL) and SCYNEXIS (NASDAQ:$SCYX) are both small-cap companies competing in the medical sector. So how do these two rivals stack up against each other? Let’s look at the numbers. Profitability Impax Laboratories has ... [Read]
Is Impax Laboratories a Buy At $16?
Impax Laboratories (NASDAQ:$IPXL) currently has a going rate of $20.75 per share. This could be a shaky proposition for some investors. However, there may be another way to get in on the drug manufacturer’s stock. ... [Read]
Impax Laboratories Inc: A Technical Snapshot
In the most recent session, shares of Impax Laboratories Inc. (NASDAQ:$IPXL) dropped -$0.83, a volatility of -3.87%. Prices recently reached $20.62 on a volume of 3,190,000. Some investors may value creating innovative and individual strategies ... [Read]
Looking Forward at Impax Laboratories Inc.
During trading today, shares of Impax Laboratories Inc. (NASDAQ:$IPXL) saw a recent bid of $21.17. In total, the stock has moved 0.81% or $0.17 from open. 49,456 shares have traded hand during the session. When ... [Read]
Cantor Fitzgerald Restates Impax Laboratories’ ‘Buy’ Rating
On Monday, research analysts Cantor Fitzgerald restated a ‘Buy’ rating for Impax Laboratories, Inc. (NASDAQ:$IPXL). Cantor Fitzgerald also set a price target of $25.00, indicating a potential 8.70% from the stock’s current position. The rating ... [Read]
Impax Laboratories in Talks About Merger with Amneal Pharmaceuticals LLC
The Wall Street Journal has reported Thursday that generic drugmaker Impax Laboratories (NASDAQ:$IPXL) has entered talks with Amneal Pharmaceuticals (Privately Traded) about a possible merger. IPXL is a pharmaceutical company specializing in developing, manufacturing and ... [Read]
Adamis Pharmaceuticals’ Shares Hits New Highs After Allergic-Reaction Treatment Drug Gains FDA Approval
Investors in Adamis Pharmaceuticals Corp. (NASDAQ:$ADMP) were probably celebrating yesterday as the company’s shares flew through the roof by a whopping 53%, hitting a one-year high. The rise was largely due to Adamis’ announcement that ... [Read]